Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors : vimarsana.com

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...

Related Keywords

Ivrea , Piemonte , Italy , United States , Japan , Spain , Zhejiang , China , Haiyan , Yunnan , Millburn , Pennsylvania , Switzerland , Zaragoza , Baja California , Mexico , Philadelphia , Sasayama , Hyogo , America , Michael Meo , Tina Deignan , Theodore Laetsch , Isabella Zinck , Richard Jarvis , Marlena Abdinoor , Nicole Zinsli Somm , Sloan Simpson , Parag Mahanti , Satoshi Sugimoto , Imke Kappes , Jonathan Graham , Linkedin , Elsevier Inc , Drug Administration , Developmental Therapeutics Program , Facebook , Exchange Commission , Novartis , Instagram , Therapeutic Area Head , Radioligand Therapy , Metab Clin North , Survival Outcomes , Patients With Neuroendocrine Tumors , Related Cancer , Gastroenteropancreatic Neuroendocrine , Evaluate Safety , Adolescent Patients With , Accessed March , Full Prescribing , Product Characteristics , Clinical Radiation , Markets ,